For LUCENTIS® (ranibizumab) prescribing information click here

For ▼Beovu® (brolucizumab) GB and NI prescribing information click here

For Luxturna®▼(voretigene neparvovec) prescribing information click here

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

At Novartis, we are dedicated to discovering, developing and manufacturing innovative treatments and technologies to help improve patients’ lives, protecting their vision and independence.1–5

We are committed to building strong, lasting healthcare system partnerships; with everyone involved in ophthalmic patient care.

We are passionate about working with ophthalmology healthcare professionals to shape a future for patients.

Sight is precious. Together, we unite on a mission* to save sight.

Lucentis logo

Our portfolio started with Lucentis, which in 2007 became the first anti-VEGF to be approved for diabetic macular oedema (DMO) in the UK,6 then becoming the first to receive approval for proliferative diabetic retinopathy (PDR) in 2019. Lucentis is currently an anti-VEGF with the broadest range of retinal indications compared to available ophthalmic anti-VEGF currently on the market.

Visit portal

January 2007

Luxturna logo

In 2018 Luxturna launched, the first approved gene therapy for inherited retinal dystrophy.7

Visit portal

November 2018

Beovu logo

In 2020 we expanded our portfolio by launching Beovu, which was recommended as a treatment option for adults with wet age-related macular degeneration (AMD) by National Institute of Health and Care Excellence(NICE) and accepted by the Scottish Medicines Consortium (SMC) in 2021.3,8

Beovu has been approved for patients with visual impairment due to DMO in March 2022 by the electronic medicines consortium (EMC), and in March 2022 (for NI) and April 2022 (for GB) by the Medicines and Healthcare products Regulatory Agency (MHRA).9-11

Visit portal

February 2020

April 2022

 

Save the date

Join us for a range of meetings hosted throughout the year, which promise to be educational and engaging.

Register your interest

 
Calendar icon to register for important 'Save the Date' events

 

Missed a meeting? Watch the recording

Please follow this link to find a range of recorded webinars for Beovu and Lucentis, as well as an ophthalmology podcast series.

Webinar highlights

 
'Replay' icon to show that webinars can be played on demand

 

Resources to support you and your patients

Beovu branding banner to illustrate resources which are available to view or download.

Beovu resources

Resources for HCPs, and for HCPs to provide to patients who have been prescribed Beovu.

See more >

Lucentis branding banner - image of eye,  to illustrate Lucentis resources which are available to view or download

LUCENTIS resources

Resources for HCPs, and for HCPs to provide to patients who have been prescribed LUCENTIS.

See more >

Luxturna branding banner  to illustrate Luxturna resources which are available to view or download

Luxturna resources

Useful resources for information on identifying and referring patients.

See more >

*The mission of Novartis in the field of ophthalmology is to discover, develop and manufacture innovative products to improve eye health and enhance people’s lives.

AMD, age-related macular degeneration; DMO, diabetic macular oedema; EMC, electronic medicines compendium; GB, Great Britain; HCP, healthcare professional; MHRA, Medicines and Healthcare products Regulatory Agency; NICE, National Institute of Health and Care Excellence; NI, Northern Ireland; PDR, proliferative diabetic retinopathy; SMC, Scottish Medicines Consortium.

  1. Ferrara N, et al. Retina 2006; 26(8): 859-870.
  2. Submacular Surgery Trials Research Group. Ophthalmic Epidemiol 2007; 14(4): 205-215. doi: 10.1080/09286580701502970.
  3. National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at https://www.nice.org.uk/guidance/ta672. [Accessed December 2021].
  4. Suñer IJ, et al. Retina 2017; 37(6): 1126-1133.
  5. Novartis UK. 2021. Company History I Novartis UK. [online) Available at: [Accessed December 2021].
  6. Lucentis (ranibizumab) Summary of Product Characteristics, April 2022.
  7. Luxturna® (voretigene neparvovec) Summary of Product Characteristics.
  8. Scottish Medicines Consortium. Available at https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu... [Accessed December 2021].
  9. Novartis. Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema. Available at: https://www.novartis.com/news/media-releases/novartis-announces-european... [Accessed May 2022].
  10. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  11. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
Rate this content: 
No votes yet
UK | May 2022 | 210794
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]